Novartis and UK-based Relation forge R&D deal worth up to $1.7bn [Yahoo! Finance]
Monte Rosa Therapeutics, Inc. (GLUE)
Company Research
Source: Yahoo! Finance
Through the agreement, the Swiss big pharma company will hand over $55m in upfront, equity investment and R&D funding payments for the global development and commercialisation rights to any resulting targets created through this partnership. Alongside this upfront payment, Relation will be eligible to receive up to $1.7bn in milestone payments, as well as tiered royalties on net sales of any products that make it to market. In exchange for Novartis' financial input, Relation will harness its AI-powered drug discovery platform, Lab-in-the-Loop, which processes multi-omic, patient-derived data to identify and validate first-in-class targets. Though neither party involved in this deal has specified the exact indications that will be targeted with the new therapeutics, , some diseases with large markets in the atopic category include asthma, allergic rhinitis and atopic dermatitis. Another aspect of Novartis and Relation's collaboration will centre around observational studies, w
Show less
Read more
Impact Snapshot
Event Time:
GLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GLUE alerts
High impacting Monte Rosa Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
GLUE
News
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its "sell (d)" rating reaffirmed by analysts at <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Monte Rosa: Looking Mispriced After Big Pharma Validation [Seeking Alpha]Seeking Alpha
- Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic Diseases [Yahoo! Finance]Yahoo! Finance
- Monte Rosa Therapeutics Presents Preclinical Data at AHA Scientific Sessions 2025 on the Potential of MRT-8102, a NEK7-directed Molecular Glue Degrader, to Treat Cardiovascular and Cardiometabolic DiseasesGlobeNewswire
- Monte Rosa Therapeutics (NASDAQ:GLUE) had its price target raised by analysts at Wells Fargo & Company from $10.00 to $13.00. They now have an "equal weight" rating on the stock.MarketBeat
GLUE
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/14/25 - Form SCHEDULE
- 11/12/25 - Form SCHEDULE
- GLUE's page on the SEC website